Abstract: A method for detecting an artificially induced neuromuscular response in a subject includes receiving a mechanomyography (MMG) output signal from a mechanical sensor in contact with a muscle of the subject; applying one or more conditioning filters to the MMG output signal to generate a conditioned signal and analyzing the conditioned signal to identify one or more candidate waveforms. Each candidate waveform meets one or more analog or digital signal characteristic criteria associated with an artificially induced neuromuscular response. The method then compares a first candidate waveform to a second candidate waveform to determine a degree of similarity between the first and second candidate waveforms, and provides an alert to a user that indicates detection of the artificially induced neuromuscular response when the degree of similarity exceeds a predetermined threshold.

Abstract: An infusion system having an integrated inserter and infusion set (10) for containing and placing a flexible catheter (40), and a retractable introducer needle (26), wherein the catheter (40) is isolated from movement after placement. The integrated inserter and infusion set (10) includes a hub (20), having a user push button (30) to activate the device for catheter (40) placement. An adhesive liner (34) can be provided to cover an adhesive layer (36), such as pressure sensitive adhesive (PSA), on the bottom of the device (10).

Abstract: Methods for treating Fuchs endothelial corneal dystrophy (“FECD”), and medications that promote healing in FECD patients following descemetorhexis.

Abstract: A self-sanitizing chair is shown and described. The chair may comprise a seating surface, legs, arm rest, head rest, and a sanitizing system. The latter may include a UV light source and a sanitizing fluid dispensing system. UV light and sanitizing fluid are applied to surfaces of the chair contacted by a human user. Indicating lights indicate when sanitizing is being performed, when sanitizing fluid is drying, and when the chair is ready for the next user. A control circuit operates the indicating lights and includes an occupant sensor. Sanitizing is inhibited in the presence of an occupant and commenced when the occupant has left the chair.

Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

Abstract: The present disclosure relates to methods of manufacture for producing anti-IL-12/IL-23p40 antibodies, e.g., the anti-IL-12/IL-23p40 antibody ustekinumab, and specific pharmaceutical compositions of the antibody.

Abstract: The present invention relates to methods of manufacture for producing anti-TNF antibodies, e.g., the anti-TNF antibody golimumab, and specific pharmaceutical compositions of the antibody.

Abstract: Methods of preparing a nutritional product which contain a lipophilic nutrient are disclosed. The nutritional product is made using a fortifying powder containing the lipophilic nutrient, a monoglyceride and diglyceride (“MDG”) oil, a phospholipid, and a carrier. The fortifying powder enhances the digestive absorption of the lipophilic nutrient when the nutritional product is consumed. The fortifying powder simplifies the process of manufacturing the nutritional product, as the fortifying powder can be added at a suitable stage of the process with other powdered ingredients. The fortifying powder may be manufactured in bulk and stored for later use, thereby improving manufacturing efficiencies. The fortifying powder and methods of preparing the fortifying powder are also presented.

Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

Abstract: Methods of preparing a nutritional product which contain a lipophilic nutrient are disclosed. The nutritional product is made using a fortifying powder containing the lipophilic nutrient, a monoglyceride and diglyceride (“MDG”) oil, a phospholipid, and a carrier. The fortifying powder enhances the digestive absorption of the lipophilic nutrient when the nutritional product is consumed. The fortifying powder simplifies the process of manufacturing the nutritional product, as the fortifying powder can be added at a suitable stage of the process with other powdered ingredients. The fortifying powder may be manufactured in bulk and stored for later use, thereby improving manufacturing efficiencies. The fortifying powder and methods of preparing the fortifying powder are also presented.

Abstract: A self-sanitizing chair is shown and described. The chair may comprise a seating surface, legs, arm rest, head rest, and a sanitizing system. The latter may include a UV light source and a sanitizing fluid dispensing system. UV light and sanitizing fluid are applied to surfaces of the chair contacted by a human user. Indicating lights indicate when sanitizing is being performed, when sanitizing fluid is drying, and when the chair is ready for the next user. A control circuit operates the indicating lights and includes an occupant sensor. Sanitizing is inhibited in the presence of an occupant and commenced when the occupant has left the chair.

Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

Abstract: The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.

Abstract: The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.

Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

Abstract: The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care.

Abstract: Methods of preparing a nutritional product which contain a lipophilic nutrient are disclosed. The nutritional product is made using a fortifying powder containing the lipophilic nutrient, a monoglyceride and diglyceride (“MDG”) oil, a phospholipid, and a carrier. The fortifying powder enhances the digestive absorption of the lipophilic nutrient when the nutritional product is consumed. The fortifying powder simplifies the process of manufacturing the nutritional product, as the fortifying powder can be added at a suitable stage of the process with other powdered ingredients. The fortifying powder may be manufactured in bulk and stored for later use, thereby improving manufacturing efficiencies. The fortifying powder and methods of preparing the fortifying powder are also presented.